Mr. Chair, in considering the regulatory decision in regard to the AstraZeneca vaccine, the regulator examined the evidence provided through the clinical trials, as I noted. Additional evidence was provided through real-world experience, including through structured studies. On that basis, the regulator determined that the benefits outweighed the risks and authorized the vaccine for use in people 18 years of age and older.
On March 12th, 2021. See this statement in context.